Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 16 10 2019
accepted: 21 01 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 9 3 2021
Statut: epublish

Résumé

Natural Killer (NK) cells play an important role in antiviral defense and their potent effector function identifies them as key candidates for immunotherapeutic interventions in chronic viral infections. Their remarkable functional agility is achieved by virtue of a wide array of germline-encoded inhibitory and activating receptors ensuring a self-tolerant and tunable repertoire. NK cell diversity is generated by a combination of factors including genetic determinants and infections/environmental factors, which together shape the NK cell pool and functional potential. Recently a genetic polymorphism at position -21 of HLA-B, which influences the supply of HLA-E binding peptides and availability of HLA-E for recognition by the inhibitory NK cell receptor NKG2A, was shown to have a marked influence on NK cell functionality in healthy human cytomegalovirus (HCMV) seronegative Caucasian individuals. In this study, -21 methionine (M)-expressing alleles supplying HLA-E binding peptides were largely poor ligands for inhibitory killer immunoglobulin-like receptors (KIRs), and a bias to NKG2A-mediated education of functionally-potent NK cells was observed. Here, we investigated the effect of this polymorphism on the phenotype and functional capacity of peripheral blood NK cells in a cohort of 36 African individuals with human immunodeficiency virus type 1 (HIV-1)/HCMV co-infection. A similarly profound influence of dimorphism at position -21 of HLA-B on NK cells was not evident in these subjects. They predominantly expressed African specific HLA-B and -C alleles that contribute a distinct supply of NKG2A and KIR ligands, and these genetic differences were compounded by the marked effect of HIV-1/HCMV co-infection on NK cell differentiation. Together, these factors resulted in a lack of correlation of the HLA-B -21 polymorphism with surface abundance of HLA-E and loss of the NK cell functional advantage in subjects with -21M HLA-B alleles. Instead, our data suggest that during HIV/HCMV co-infection exposure of NK cells to an environment that displays altered HLA-E ligands drives adaptive NKG2C+ NK cell expansions influencing effector responses. Increased efforts to understand how NK cells are functionally calibrated to self-HLA during chronic viral infections will pave the way to developing targeted therapeutic interventions to overcome the current barriers to enhancing immune-based antiviral control.

Identifiants

pubmed: 32132995
doi: 10.3389/fimmu.2020.00156
pmc: PMC7041644
doi:

Substances chimiques

HLA-B Antigens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

156

Subventions

Organisme : Medical Research Council
ID : MR/K012037/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K012037
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI147778
Pays : United States
Organisme : Medical Research Council
ID : MR/M008614
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI144371
Pays : United States

Informations de copyright

Copyright © 2020 Cubero, Ogbe, Pedroza-Pacheco, Cohen, Haynes, Borrow and Peppa.

Références

Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Immunity. 2015 Oct 20;43(4):634-45
pubmed: 26488815
Cell Host Microbe. 2016 May 11;19(5):686-95
pubmed: 27173934
Curr Opin Virol. 2016 Feb;16:15-23
pubmed: 26590692
Front Immunol. 2018 Mar 16;9:474
pubmed: 29616021
Immunity. 1999 Jun;10(6):661-71
pubmed: 10403641
Eur J Immunol. 1999 Feb;29(2):537-47
pubmed: 10064069
J Infect Dis. 2006 Jul 1;194(1):38-41
pubmed: 16741880
J Infect Dis. 2007 Jan 1;195(1):158-9; author reply 159-60
pubmed: 17152020
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
Science. 2000 Feb 11;287(5455):1031
pubmed: 10669413
Curr HIV/AIDS Rep. 2016 Apr;13(2):85-94
pubmed: 27002078
Eur J Immunol. 2012 Feb;42(2):447-57
pubmed: 22105371
Science. 2018 Jan 5;359(6371):86-90
pubmed: 29302013
Hum Immunol. 1997 Jan;52(1):33-40
pubmed: 9021407
J Immunol. 2019 Oct 15;203(8):2301-2309
pubmed: 31519864
J Immunol Res. 2014;2014:298569
pubmed: 24839609
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2886-91
pubmed: 15699323
PLoS Pathog. 2018 Sep 4;14(9):e1007257
pubmed: 30180214
Clin Immunol. 2009 Nov;133(2):238-44
pubmed: 19762282
Blood. 2013 Apr 4;121(14):2678-88
pubmed: 23325834
Nat Immunol. 2018 May;19(5):453-463
pubmed: 29632329
EMBO J. 1999 Aug 2;18(15):4250-60
pubmed: 10428963
J Virol. 2011 Apr;85(7):3367-74
pubmed: 21248048
J Infect Dis. 2012 Jun 15;205(12):1797-805
pubmed: 22492862
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5140-5
pubmed: 11309482
Nat Commun. 2018 Aug 7;9(1):3137
pubmed: 30087334
J Immunol. 2013 Sep 1;191(5):2708-16
pubmed: 23918974
J Infect Dis. 2015 Sep 15;212(6):845-52
pubmed: 25748324
Curr Opin Immunol. 2018 Feb;50:102-111
pubmed: 29413815
J Virol. 2009 Sep;83(17):8705-12
pubmed: 19553339
Cell Rep. 2018 Aug 21;24(8):1967-1976.e4
pubmed: 30134159
Immunity. 2015 Mar 17;42(3):443-56
pubmed: 25786176
Blood. 2006 May 1;107(9):3624-31
pubmed: 16384928
J Immunol. 1998 May 15;160(10):4951-60
pubmed: 9590243
Clin Exp Immunol. 2013 Dec;174(3):414-23
pubmed: 23952339
Blood. 2010 Nov 11;116(19):3853-64
pubmed: 20696944
J Infect Dis. 2009 Sep 1;200(5):820-6
pubmed: 19619059
Nature. 2011 Apr 28;472(7344):495-8
pubmed: 21499264

Auteurs

Elia Moreno Cubero (EM)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.

Ane Ogbe (A)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.

Isabela Pedroza-Pacheco (I)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.

Myron S Cohen (MS)

University of North Carolina School of Medicine, Chapel Hill, NC, United States.

Barton F Haynes (BF)

Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States.

Persephone Borrow (P)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.

Dimitra Peppa (D)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Department of HIV, Mortimer Market Centre, Central and North West London NHS Foundation Trust (CNWL),, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH